Gene therapy patent chain-of-title, assignment or exclusive license, patent scope, territory, term, encumbrances, and implementation rights.
Due Diligence
Investor release requires medical, legal, financial, IP, and regulatory evidence.
Gene therapy patent chain-of-title, assignment or exclusive license, patent scope, territory, term, encumbrances, and implementation rights.
Due Diligence
Investor release requires medical, legal, financial, IP, and regulatory evidence.
Stemedica corporate, IP, clinical, manufacturing, cGMP, safety, trial, product, commercial, and territory-rights verification.
Hospital licensing, SAHPRA, HPCSA, ethics, POPIA, environmental, water, energy, waste, zoning, medical tourism, malpractice, and visiting-doctor approvals.
No unverified medical outcomes, unapproved advanced therapy marketing, unvalidated capex numbers, or unverified partner claims should be used in investor or patient-facing materials.
Governance
Advanced therapy, costing, and partner claims require evidence before investor release.
Gene therapy is treated as a Tygan-owned or Tygan-controlled patent platform from project start. Medical pathways remain subject to clinical governance, SAHPRA, ethics, POPIA, patient consent, scientific validation, and independent legal review.